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ABSTRACT  13 
Conjugative plasmids are the main players in horizontal gene transfer in Gram-14 
negative bacteria. DNA transfer tools constructed on the basis of such plasmids enable gene 15 
manipulation even in strains of clinical or environmental origin, which are often difficult to 16 
work with. The conjugation system of the IncM plasmid pCTX-M3 isolated from a clinical 17 
strain of Citrobacter freundii has been shown to enable efficient mobilization of oriTpCTX-M3-18 
bearing plasmids into a broad range of hosts comprising Alpha-, Beta-, and 19 
Gammaproteobacteria. We constructed a helper plasmid pMOBS mediating such 20 
mobilization with an efficiency up to 1000-fold higher than that achieved with native pCTX-21 
M3. We also constructed E. coli donor strains with chromosome-integrated conjugative 22 
transfer genes: S14 and S15, devoid of one putative regulator (orf35), and S25 and S26, 23 
devoid of two putative regulators (orf35 and orf36) of the pCTX-M3 tra genes. Strains S14 24 
and S15, and S25 and S26 are, respectively, up to 100 and 1000 times more efficient in 25 
mobilization than pCTX-M3. Moreover, they also enable plasmid mobilization to the Gram-26 
positive bacteria Bacillus subtilis and Lactococcus lactis. Additionally, the constructed E. 27 
coli strains carried no antibiotic resistance genes that are present in pCTX-M3 to facilitate 28 
manipulations with antibiotic-resistant recipient strains, such as those of clinical origin. To 29 
demonstrate possible application of the constructed tool, an antibacterial conjugation-based 30 
system was designed. Strain S26 was used for introduction of a mobilizable plasmid coding 31 
for a toxin, resulting in the elimination of over 90% of recipient E. coli cells.  32 
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IMPORTANCE 34 
The conjugation of donor and recipient bacterial cells resulting in conjugative 35 
transfer of mobilizable plasmids is the preferred method enabling the introduction of DNA 36 
into strains for which other transfer methods are difficult to establish (e.g., clinical strains). 37 
We have constructed E. coli strains carrying the conjugation system of the IncM plasmid 38 
pCTX-M3 integrated into the chromosome. To increase the mobilization efficiency up to 39 
1000-fold, two putative regulators of this system, orf35 and/or orf36, were disabled. The 40 
constructed strains broaden the repertoire of tools for the introduction of DNA into the 41 
Gram-negative Alpha-, Beta-, and Gammaproteobacteria, as well as into Gram-positive 42 
bacteria such as Bacillus subtilis and Lactococcus lactis. The antibacterial procedure based 43 
on conjugation with the use of the orf35- and orf36-deficient strain lowered the recipient cell 44 
number by over 90% owing to the mobilizable plasmid-encoded toxin. 45 
 46 
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INTRODUCTION 48 
The transfer of conjugative plasmids is one of the major mechanisms of horizontal 49 
gene transfer between bacteria, which plays a key role in bacterial ecology and evolution. 50 
Notably, it can also be utilized for biotechnological and laboratory purposes. For a 51 
conjugative DNA transfer event, several elements are necessary in the donor cell of a Gram-52 
negative bacterium: i/ a DNA transporter of the type IV secretion system (T4SS) with the 53 
pilus responsible for establishing physical contact between the mating cells; ii/ a relaxase 54 
complex that nicks DNA, prepares it for transport and enables the start of DNA replication; 55 
iii/ oriT, a specific DNA sequence where the process of transfer begins, recognized and cut 56 
by the relaxase complex to generate single-stranded DNA with the relaxase covalently 57 
bound at its 5’ end; and iv/ a coupling protein that brings together the DNA - relaxase 58 
complex and the T4SS transporter (1). Conjugative plasmids encode all the elements 59 
necessary for their conjugative transfer during mating. Such plasmids can also serve as 60 
helpers in the mobilization and transfer of mobilizable plasmids bearing compatible oriT 61 
sequences. Apart from their importance in nature, mobilizable plasmids are commonly used 62 
in laboratories because, being transferred as single-stranded DNA, they avoid the host 63 
restriction system (2, 3).  64 
Genetic manipulations performed on diverse bacteria require effective methods for 65 
introducing DNA into recipient cells. Although many bacteria are not naturally competent, 66 
laboratory bacterial strains are easy to manipulate using methods such as chemical 67 
transformation and electroporation. However, these methods are often inefficient on clinical 68 
or environmental isolates. In this case, conjugative transfer is the most powerful method for 69 
introducing DNA into bacterial cells, and one of the most popular systems is based on the 70 
broad-host-range IncP-1α plasmid RP4/RK2 (4). Its conjugative transfer system is used to 71 
introduce DNA into a broad range of hosts, including virtually any Gram-negative bacteria, 72 
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certain Gram-positive ones (5), yeast (6, 7), and even mammalian cells (8). However, new 73 
and/or alternative systems in the repertoire of laboratory methods are still required to 74 
broaden the spectrum of recipients to include “difficult” bacteria such as multiresistant 75 
isolates and also clinical or environmental strains already bearing the IncP-1α plasmids. 76 
Multiresistant clinical strains pose one of the greatest health risks due to a lack of 77 
effective therapies. Therefore, novel antibacterial treatments are urgently needed. One of 78 
such alternatives is the bacterial conjugation-based technology (BCBT) that relies on a 79 
transfer of killing agents during bacterial conjugation (9). In principle, it works as a Trojan 80 
horse: acquisition of a mobilizable plasmid by the recipient should result in its death. 81 
Simultaneously, the donor is protected from the deleterious action of the killing agent by an 82 
agent-specific mechanism. The toxin - antidote (TA) systems (10) of the plasmid addiction 83 
modules can be used in BCBT. The Zeta-Epsilon module, the TA system of the 84 
streptococcal pSM19035 plasmid, has been shown to act as a plasmid addiction system not 85 
only in various Firmicutes species but also in E. coli (11). Zeta toxin is a kinase 86 
phosphorylating the peptidoglycan precursor UDP-N-acetylglucosamine (UNAG), which 87 
inhibits cell wall synthesis (12). The Zeta-encoding gene located on a mobilizable plasmid 88 
and introduced via conjugation into recipient bacteria may be used in BCBT. Noteworthy, in 89 
Gram-negative bacteria no homologs of the gene encoding Epsilon, the antidote of the Zeta 90 
toxin, have been found (13). 91 
The IncM plasmid pCTX-M3 (GenBank Acc. No. AF550415) was isolated in 1996 92 
from a clinical Citrobacter freundii strain in Poland as a vector of the blaCTX-M-3 gene 93 
encoding an extended-spectrum β-lactamase (14, 15). Plasmids of the IncL and IncM groups 94 
(formerly constituting a single IncL/M group) are widespread in bacterial populations 95 
worldwide and are responsible for the dissemination of different antibiotic resistance genes 96 
(16–18), mostly through the conjugative transfer system (19). In addition to blaCTX-M-3, 97 
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pCTX-M3 bears other genes, conferring resistance to β-lactams (blaTEM-1), aminoglycosides 98 
(aacC2, aadA2, and armA) and trimethoprim-sulfamethoxazole (dhfrA12 and sul1) (15). 99 
Recently, the host range of the pCTX-M3 replicon was verified to be much narrower than 100 
previously determined (20) and restricted to Enterobacteriaceae (21). However, the range of 101 
hosts of the conjugative transfer system of this plasmid is much broader than the host range 102 
of its replicon and comprises Alpha-, Beta-, and Gammaproteobacteria (21). The closest 103 
homologs of the pCTX-M3 conjugation system, besides other IncM and IncL plasmids, are 104 
the IncI1 representatives R64 and ColIb-P9 (21), prototypes of the I-type conjugation system 105 
(22). pCTX-M3 is able to mobilize plasmids bearing oriTColIb-P9 and vice versa, ColIb-P9 106 
mobilizes plasmids containing oriTpCTX-M3 (15), in both instances with low efficiency. 107 
Elements of the conjugative transfer system of pCTX-M3 are encoded in two distant 108 
regions, the tra and trb operons (15). Surprisingly, the replacement of orf35, a gene located 109 
in the leading region and unnecessary for the conjugative transfer of pCTX-M3, with the cat 110 
gene increased the mobilization of an oriTpCTX-M3-bearing plasmid one-hundred-fold. 111 
Moreover, a similar replacement of orf36 from the tra region had no impact on the 112 
conjugative transfer of pCTX-M3 but led to a ten-fold increase in the mobilization 113 
efficiency (21). The deletion of orf35 increased the transcript levels of the nikA, nikB, and 114 
traH genes, whereas deletion of orf36 increased the traH transcript level. The tra genes 115 
located downstream of traH most likely also are subject to an orf35- and orf36-dependent 116 
regulation (21), but its mode is currently unknown. In view of that greatly increased 117 
mobilization efficiency of pCTX-M3 devoid of orf35 alone or of orf35 and orf36 was a 118 
promising candidate for the preparation of a novel conjugative donor strain. 119 
Here, we present the construction of a helper plasmid, pMOBS, and a set of donor E. 120 
coli strains, S14 and S15, all devoid of orf35, and S25 and S26, devoid of orf35 and orf36, 121 
as new tools for plasmid mobilization that are up to 1000-fold more efficient than parental 122 
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pCTX-M3. We show that the constructed strains enable conjugative transfer of mobilizable 123 
plasmids into multiresistant clinical strains. Additionally, we found that a mobilizable 124 
plasmid encoding the Zeta toxin is highly efficient in BCBT against a laboratory E. coli 125 
strain, but not equally effective against several clinical E. coli strains. We also show that the 126 
range of recipients in the conjugative transfer system is broader than previously determined 127 
and comprises not only Alpha-, Beta-, and Gammaproteobacteria but also Gram-positive 128 
bacteria such as Bacillus subtilis and Lactococcus lactis.  129 
 130 
131 
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RESULTS 132 
We have shown previously (21) that in the presence of the helper plasmid pCTX-133 
M3orf35::cat (devoid of a functional orf35, the first gene of the pCTX-M3 leading region), 134 
pToriT, a broad-host-range plasmid with oriTpCTX-M3, was mobilized into the recipients 135 
Escherichia coli or Agrobacterium tumefaciens, with almost 100-fold higher efficiency than 136 
it was in the presence of intact pCTX-M3. Deletion of another gene, orf36, resulted in ca. 137 
10-fold increase in the mobilization efficiency to both recipients (21). We have also shown 138 
that orf46 located next to the trb region, is dispensable for conjugative transfer and that its 139 
deletion does not influence plasmid mobilization. Therefore, we decided to use the 140 
orf46::cat cassette for antibiotic selection of a pCTX-M3-based efficient helper plasmid 141 
devoid of the mobilization limiting orf35 and orf36. The latter, due to its localization in the 142 
middle of the tra operon, was deleted at a later stage of plasmid construction. 143 
Construction of the helper plasmid pMOBS and the E. coli donor strain S14. 144 
First, the pLMAB212 plasmid was constructed by multistep sub-cloning of the tra, trb, and 145 
rep regions from pCTX-M3orf46::cat (Figs. S1A and S1B,); pLMAB212 contains the IncM 146 
replicon, lacks orf35, and has orf46 replaced by cat to allow for subsequent selection of 147 
transformants. The cat gene was integrated with two flanking FRT sequences (the Flp 148 
recombinase recognition targets) and therefore it could be removed in the presence of Flp 149 
recombinase (21, 23). Notably, pLMAB212 also lacks mobile genetic elements (insertion 150 
sequences and transposons) and antibiotic resistance genes from pCTX-M3, except for 151 
blaTEM-1. 152 
The structure of oriTpCTX-M3 was predicted based on sequence similarity with oriT of 153 
R64, an IncI1 plasmid (Fig. S1C). This enabled the introduction of four mutations in the 154 
predicted nick region (ACATCTTGT → CGAACTAGT) in the oriT sequence of 155 
pLMAB212 to construct pMOBS. These changes made oriT nonfunctional and introduced a 156 
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unique SpeI restriction site (A↓CTAGT). The ability of pMOBS to self-transfer was thereby 157 
eliminated, but the plasmid mobilization efficiency remained unchanged (Fig. 1). 158 
To construct a convenient E. coli donor strain, a pMOBS fragment comprising the 159 
tra and trb genes, attP and cat, was integrated into the DH5α chromosome to yield the S14 160 
strain (Fig. S2A). The correctness of the integration was verified by PCR (Fig. S2B) using 161 
specific primers indicated in Table 3. The S14 chromosome carries the conjugative transfer 162 
regions: tra - pos. 31300 – 54398, with oriT mutated in pos. 31626, 31629, 31631, and 163 
31632; and trb - pos. 84101 – 89015, according to the pCTX-M3 GenBank sequence (Acc. 164 
No. AF550415). Additionally, the S14 strain is resistant to chloramphenicol. 165 
Mobilization efficiency of the pMOBS helper plasmid and the S14 strain. E. coli 166 
strains DH5α(pCTX-M3), DH5α(pMOBS), and S14 were used as helpers in the 167 
mobilization of pToriT, a vector based on the broad-host-range and low-copy-number 168 
replicon oriVpBBR1 (24). As shown in Fig. 2, the E. coli strain with pMOBS as a helper 169 
plasmid mobilized pToriT almost 1000-fold more efficiently, and the S14 helper strain ca. 170 
100-fold more efficiently in comparison with the strain with pCTX-M3. 171 
Construction of S14-derived strains. The S14 strain is devoid of orf35 regulating 172 
the expression of the tra genes in pCTX-M3 (21). To delete the second regulatory gene, 173 
orf36, we first removed the cat gene from S14 (Cm
r
; Δorf35, orf46::cat) to obtain the S15 174 
strain (Cm
s
; Δorf35, Δorf46). Then, we constructed an orf36 deletion mutant by replacing 175 
this gene with cat to obtain the S25 strain (Cm
r
; Δorf35, orf36::cat, Δorf46). Finally, cat was 176 
removed from S25, resulting in the S26 strain (Cm
s
; Δorf35, Δorf36, Δorf46) (Fig. S2C). 177 
Mobilization efficiency of helper strains S15, S25, and S26. We tested the 178 
efficiency of pToriT mobilization by the newly constructed helper strains S15, S25, and S26 179 
in matings with the JE2571Rif
r 
E. coli recipient and compared with that of the S14 strain 180 
(Fig. 3). Additionally, we verified the pToriT mobilization efficiency in interspecies matings 181 
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using the constructed helper strains as donors and representatives of Alpha-, Beta-, and 182 
Gammaproteobacteria as recipients. The recipients tested were: A. tumefaciens, Cupriavidus 183 
necator (previously Ralstonia eutropha) and Pseudomonas putida (as a non-enteric 184 
Gammaproteobacterium). As shown in Figs. 3 and S3A, when S25 or S26 were the donors, 185 
the mobilization efficiencies were ca. 50-100× higher than those of the S14 or S15 donors 186 
regardless of the recipient. 187 
Additionally, we tested the ability of the S14, S15, S25, and S26 helper strains to 188 
mobilize pABB19oriT, a high-copy-number plasmid. Again, strains S25 and S26 were 100× 189 
more effective as donors than were S14 and S15 (Fig. S3B). 190 
The S25 helper strain enables plasmid mobilization to Gram-positive bacteria. 191 
Because the pCTX-M3-derived system could efficiently mobilize plasmids into a wide range 192 
of Gram-negative bacteria, we sought to determine its ability to transfer plasmids into Gram-193 
positive bacteria as well. For that purpose, we used pBSUoriT, which is a shuttle vector that 194 
replicates in E. coli using oriVpMB1 and uses oriVpAMβ1 for replication in Gram-positive 195 
bacteria with low GC content. One of the most efficient helper strains, S25 (Cm
r
) bearing 196 
pBSUoriT, was used as a donor in mating experiments. As recipients, we used a B. subtilis 197 
subsp. subtilis 168-derived laboratory strain YB1015Rif
r
, a biofilm-forming B. subtilis 198 
subsp. spizizeni strain PCM2021Rif
r
, and rifampicin-resistant L. lactis, a derivative of the 199 
laboratory plasmid-free strain IL1403. In each mating, interspecies transconjugants were 200 
selected (Fig. 4). Interestingly, a large difference in the mobilization efficiencies was 201 
observed between the two B. subtilis strains. PCM2021Rif
r
 gave transconjugants with a 202 
mobilization efficiency four orders of magnitude higher (over 10
-2
/donor) than did 203 
YB1015Rif
r
. Transconjugants of L. lactis were obtained at an efficiency of ca. 10
-6
/donor. 204 
To verify the presence of pBSUoriT in the transconjugants, plasmid DNA from several B. 205 
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subtilis and L. lactis Sp
r 
Rif
r
 clones was isolated. Their restriction analysis confirmed the 206 
presence of pBSUoriT (data not shown).  207 
Additionally, to exclude the possibility that the Sp
r 
Rif
r
 clones of B. subtilis resulted 208 
from transformation due to its natural competence, we tested mobilization of pBSUoriT or 209 
pBSU1 (lacking oriTpCTX-M3) into B. subtilis YB1015Rif
r
. The appearance of the Sp
r 
Rif
r
 210 
B.subtilis clones was shown to be strictly oriTpCTX-M3 dependent (Fig. S4). 211 
 The S26 strain enables bacterial conjugation-based recipient killing. To test the 212 
usefulness of strain S26 in conjugation-based elimination of bacteria, we used pAZAKT, an 213 
oriTpCTX-M3-containing plasmid with the zeta gene coding for the toxin of the pSM19035 214 
toxin-antidote (TA) system (11). The expression of zeta was controlled by the arabinose 215 
operon PBAD promoter (25). As a donor of pAZAKT, we used strain S26 additionally 216 
carrying the pUC-epsi plasmid coding for Epsilon, the Zeta antidote. JE2571Rif
r
 was used as 217 
a recipient. To avoid the killing of donor cells, the level of Zeta must be adequately balanced 218 
to permit its inactivation by formation of complexes with Epsilon. Simultaneously, upon 219 
conjugative transfer of pAZAKT, PBAD
 
should allow the zeta gene expression and 220 
production of the toxin in recipient cells. In both the recipient and donor strains, the PBAD 221 
regulator AraC is encoded chromosomally. In the absence of arabinose, the chromosomally 222 
encoded AraC protein tightly represses the chromosomally-encoded arabinose operon 223 
araBAD by binding to the PBAD promoter (26). However, in the presence of arabinose, AraC 224 
stimulates transcription from PBAD. In fast growing E. coli cells the level of AraC is low - ca. 225 
20 molecules per cell (27). In S26(pAZAKT, pUC-epsi) cells the PBAD promoter controlling 226 
the zeta gene was on a plasmid present at 15-30 copies per cell (due to the oriVP15A), so 227 
AraC could be titrated out.  228 
Plasmid pAZAKT was mobilized by S26(pUC-epsi) into JE2571Rif
r
. In a control 229 
experiment, we used the S26(pAAKT, pUC-epsi) strain bearing the inactive zeta gene as a 230 
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donor. Additionally, the same experiment was repeated with DRifras a recipient. For 231 
both recipients, the number of pAZAKT transconjugants was ca. three orders of magnitude 232 
lower than that of the pAAKT ones, indicating zeta-dependent killing of transconjugants 233 
(Fig. 5).  234 
To determine whether arabinose supplementation was necessary to better observe the results 235 
of Zeta toxicity, we compared the efficiencies of pAAKT and pAZAKT mobilization from 236 
S26(pUC-epsi) to JE2571Rif
r
 in the presence or absence of 0.1% arabinose in conjugation 237 
medium and/or medium for transconjugants selection. The results indicated that the addition 238 
of arabinose to the conjugation medium or to the transconjugants selection medium did not 239 
affect the number of transconjugants and hence did not increase the negative effect on 240 
survival of the transconjugants (Fig. S5). 241 
To check whether the transfer of the pAZAKT and pAAKT plasmids was dependent 242 
on the conjugation system encoded by S26, in a control experiment we used DH5α(pUC-243 
epsi) as a donor. As expected, no transconjugants were detected (Fig. S6A), indicating the 244 
strict dependence of pAZAKT and pAAKT transfer on the S26 donor strain.  245 
Characteristics of the JE2571Rif
r
 transconjugants surviving pAZAKT transfer. 246 
In principle, a cell could survive the transfer of zeta either if the zeta gene became inactive 247 
or if the cell became resistant to Zeta action. To distinguish between these possibilities, both 248 
the plasmids and the host cells of ten survivor clones were investigated in more detail. All of 249 
them were found to be not only Km
r
 Rif
r
 but also Ap
r
, which suggested that they carried the 250 
pUC-epsi plasmid, probably as a cointegrate with pAZAKT.  251 
i/ Analysis of plasmids. Digestion with HindIII, HincII, and EcoRI revealed 252 
identical restriction patterns of all plasmids isolated from the survivor clones. Restriction 253 
analysis of plasmids isolated from the survivors revealed a recombination of pAZAKT and 254 
pUC-epsi within the 623-bp fragment identical in both plasmids. Additionally, the presence 255 
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of the epsilon gene in these plasmids was confirmed by PCR with primers EpsiS and EpsiE 256 
(Table 3). Moreover, sequencing of the zeta gene revealed no mutations in any of the 257 
plasmids. Finally, we showed that these plasmids could be transformed into E. coli DH5α, 258 
indicating that the presence of the antidote gene in the incoming plasmid prevents the toxic 259 
effect of Zeta.  260 
ii/ Analysis of bacterial hosts. Six survivor clones were cured of plasmids by 261 
culturing in nonselective conditions (at 37°C in LB medium with rifampicin) for 5 days with 262 
10
-3
 dilutions every 24 hours, to get Ap
s 
Km
s 
Rif
r
 cells. Next, the cured clones were 263 
transformed with pAZAKT and pUC-epsi, and transformants were selected on kanamycin-264 
containing plates. Then, 100 transformants of each clone were tested for ampicillin 265 
resistance. All the transformants were Ap
r
 and Km
r
, indicating that the establishment of 266 
pAZAKT required co-transformation with pUC-epsi (11). These results demonstrated that 267 
survivors of pAZAKT transfer did not acquire resistance to the Zeta toxin. 268 
To address the problem of recombination between pAZAKT and pUC-epsi, the 623 269 
bp-region common to both plasmids was removed from pUC-epsi to give a shortened 270 
version of the epsilon-bearing plasmid, pUC-epsiSH. This plasmid was introduced into the 271 
S26 strain which was then used to mobilize pAZAKT and pAAKT into the JE2571Rif
r
 272 
recipient. Transconjugants with pAZAKT were observed at an efficiency ca. 4200-fold 273 
lower than those with pAAKT (Fig. S6B). Plasmids from eight survivor clones were 274 
analysed. They could be introduced into DH5α by transformation, suggesting that either zeta 275 
was inactive or epsilon was additionally present in the transforming plasmid. Indeed, in four 276 
plasmids the zeta gene was disrupted: i/ in two cases, with a 4-bp (CTAG) insertion after the 277 
85
th
 codon of zeta, ii/ in two cases, with an IS1 insertion after 94
th
 or 196
th 
codon. The 278 
remaining four plasmids were found to confer resistance to ampicillin and had a higher copy 279 
number than pAZAKT, suggesting that they were recombinants with pUC-epsiSH. The 280 
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presence of epsilon was detected by PCR with EpsiS and EpsiE primers. Sequence analysis 281 
revealed that none of the survivors contained a single plasmid with an active zeta gene. 282 
Optimization of recipient killing upon mobilization of the Zeta-encoding 283 
plasmid. To optimize the mobilization-mediated Zeta killing of recipient cells conditions of 284 
the conjugation procedure were varied. S26(pUC-epsi) was used as a donor of pAZAKT and 285 
JE2571Rif
r
 was the recipient. As a control pAAKT was mobilized. We used the donor and 286 
recipient in the stationary phase of growth with the donor-to-recipient ratios of 130:1, 14:1 287 
and 0.9:1. The recipient survival rate was calculated by comparing the number of recipients 288 
(Rif
r
 cells) in the conjugation mixture after mating to their initial number. With the 289 
pAZAKT donor-to-recipients ratio equal to 0.9, no reduction of the number of JE2571Rif
r 
290 
cells was observed (Fig. 6A). With an excess of donors over recipients efficient killing of 291 
the latter was observed as their number was reduced to 35% and to 10% with the respective 292 
ratios of 14:1 and 130:1. As expected no killing was observed when the pAAKT plasmid 293 
was mobilized.  294 
Since Zeta toxin is an inhibitor of cell wall synthesis, we expected that the killing of 295 
recipient cells upon the pAZAKT transfer should be more efficient for actively dividing 296 
cells. To check this, we used JE2771Rif
r
 in the exponential phase of growth (OD600=0.4) as 297 
the recipient, with S26(pUC-epsi) serving as a donor of pAZAKT or pAAKT. The donor-to-298 
recipient ratios were 3:1, 32:1, 273:1, and 2727:1, with the number of donors constant. The 299 
respective recipient survival rates were 2.1%, 1.1%, 1%, and 0.7% when pAZAKT was 300 
mobilized, while with the pAAKT transfer the recipient number actually increased (Fig. 6B). 301 
These results confirmed, that indeed the recipient in the exponential phase of growth is more 302 
susceptible to Zeta killing.  303 
The S26 helper strain enables plasmid mobilization to multiresistant bacteria of 304 
clinical origin. Plasmid mobilization is a convenient method for introducing DNA into 305 
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environmental or clinical strains for which conventional transformation methods are 306 
ineffective. Such strains frequently contain plasmids of the IncP groups (28, 29). Since the 307 
most widely used mobilization system utilizes genes coding for the conjugative transfer 308 
system of RK2/RP4, it cannot introduce DNA into bacteria bearing plasmids from the IncP-309 
1α group. In contrast, S26, which encodes a highly efficient IncP-compatible mobilizing 310 
system from pCTX-M3, was a good candidate for a plasmid donor. To test this we used 311 
S26(pToriT) in matings with two clinical E. coli strains as recipients, 1355/2004 and 312 
1149/2004, both carrying IncP replicons as determined using the plasmid replicon typing 313 
method performed according to Carattoli et al. (30). Transconjugants were obtained for the 314 
both recipients, albeit with different efficiencies: over 10
-1
/donor for 1149/2004 and  315 
10
-4
/donor for 1355/2004 (Fig. 7).  316 
Importantly, S26 is devoid of any antibiotic-resistance determinants, which is a 317 
desired feature of mobilizing systems for introduction of DNA into clinical or environmental 318 
strains. 319 
The zeta gene transferred from the S26 strain eliminates bacteria of clinical 320 
origin. To check whether the mobilization system described above could also be used 321 
against clinical isolates, the clinical E. coli strains 1355/2004 and 1149/2004 were used as 322 
recipients. As for the JE2571Rif
r
 strain, in both cases the number of pAAKT transconjugants 323 
was higher than that of the pAZAKT ones, indicating zeta-dependent killing (Fig. 8A). That 324 
difference was 1275-fold for 1149/2004 and only 40-fold for 1355/2004. At the same time 325 
the overall efficiency of plasmid mobilization (determined for pAAKT) was ca. five orders 326 
of magnitude lower for 1355/2004 than for either 1149/2004 or JE2571Rif
r
.  327 
 The low mobilization efficiency into the 1355/2004 strain is not caused by its 328 
resident IncP plasmid. Conjugative plasmids encode mechanisms, such as entry exclusion 329 
systems acting in recipients to prevent acquisition of identical plasmid backbones (31). Such 330 
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a system could be present on the IncP plasmid residing in the 1355/2004 strain. To verify 331 
this hypothesis first, the IncP plasmid conferring tetracycline resistance in 1355/2004 was 332 
transferred by conjugation to JE2571Rif
r
. Then, three independent transconjugants of 333 
JE2571Rif
r
 with the 1355/2004 plasmid, named R
+
[E. coli 1355/2004],
 
were used as 334 
recipients in matings with the pair of donors S26(pAZAKT, pUC-epsi) and S26(pAAKT, 335 
pUC-epsi). The efficiencies of mobilization into R
+
[E. coli 1355/2004] were identical to 336 
those to JE2571Rif
r
 (Fig. 8B), indicating that the features determining the low mobilization 337 
efficiency of the oriTpCTX-M3-bearing plasmid into 1355/2004 were not encoded by the IncP 338 
plasmid.  339 
 340 
DISCUSSION 341 
Based on the I-type conjugation system of the IncM plasmid pCTX-M3 we 342 
constructed and characterized a set of bacterial strains for efficient mobilization of oriTpCTX-343 
M3-bearing plasmids. First, the mobilizing pMOBS plasmid with an inactivated oriTpCTX-M3 344 
was constructed. This plasmid bears the IncM replicon, therefore it can replicate in 345 
Enterobacteriaceae. pMOBS is devoid of orf35 found earlier to be involved in the 346 
regulation of trapCTX-M3 genes (21). The conjugation system from the pMOBS helper 347 
plasmid was also introduced into the E. coli chromosome to create the S14 donor strain. An 348 
additional deletion of orf36, a gene unique to the IncL and IncM plasmids, involved in the 349 
regulation of expression of T4SS transporter-encoding genes (21), produced strains S25 350 
(Cm
r
) and S26 (Cm
s
). These strains were ca. 50-100× more efficient as donors than was S14 351 
in matings with all Alpha-, Beta-, and Gammaproteobacteria recipients tested. Moreover, 352 
these pCTX-M3-conjugation system-based strains enabled plasmid mobilization even into 353 
the Gram-positive bacteria B. subtilis and L. lactis, indicating that the range of the recipients 354 
of the pCTX-M3 conjugation system is even broader than previously shown. 355 
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The present system is a good alternative to the S17-1/SM10 mobilization system and 356 
its derivatives based on the IncP-1α plasmid RP4/RK2, in which the entire plasmid was 357 
integrated into the E. coli chromosome using phage Mu (32). S17-1/SM10 allows the 358 
introduction of oriTRP4/RK2-bearing plasmids into various species (for examples see 30, 31). 359 
Its major drawback is that it contains all of the antibiotic resistance genes present in 360 
RK2/RP4 and can also promote the transfer of chromosomal genes because of the 361 
combination of oriTRP4/RK2 functionality and phage Mu mobilization (35–37). The strain was 362 
improved after twenty years by oriT inactivation, but it still retained the entire integrated 363 
plasmid (36, 38). The Mu activation problem was solved by inactivating the phage (37) or 364 
by constructing the broad-host-range plasmid pTA-Mob with oriTRP4/RK2 inactivated (36). 365 
In contrast to the widely used S17-1/SM10 donor strain, the newly constructed strain 366 
S14 and its derivatives S15, S25, and S26 contain neither the IS sequences nor antibiotic 367 
resistance genes present in the parental plasmid pCTX-M3. The selective marker cat was 368 
easily deleted using Flp recombinase (39) to obtain the chloramphenicol-sensitive S15 and 369 
S26 strains. Importantly, strain S26 enabled efficient plasmid mobilization also into E. coli 370 
strains of clinical origin which contained IncP-1α replicons (30) and thus could not be 371 
recipients in matings with RK2/RP4-based donors. Similarly, IncM plasmid-carrying strains 372 
cannot be recipients in matings with donors bearing pMOBS as well as with the S14 strain 373 
and its derivatives due to the presence of the entry exclusion system encoded by the traY - 374 
excA genes (40). 375 
To illustrate the usefulness of the constructed strains as potential conjugative 376 
antibacterial agents we used the S26 strain in BCBT as a vehicle of the Zeta toxin-encoding 377 
gene. The number of transconjugants upon mobilization of the active zeta-encoding plasmid 378 
pAZAKT was over three orders of magnitude lower than that of the control plasmid pAAKT 379 
indicating Zeta-dependent killing of transconjugants. Moreover, the transfer of a Zeta-380 
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encoding plasmid eliminated up to 90% of recipient E. coli cells in the stationary phase of 381 
growth when the number of donors exceeded that of recipients 130-fold. For an 382 
exponentially growing population of recipients the efficiency of killing by zeta mobilization 383 
was much higher, between ca. 98% and 99.3% for the donor excess of 3-fold to 2727-fold. 384 
One should note, however, that in a natural setting the recipient population is unlikely to 385 
comprise exclusively actively dividing cells. Nevertheless, this limitation results from the 386 
toxin used, not from the mobilizing system, thus using another killing agent could overcome 387 
this issue.  388 
Preliminary results obtained for one of the clinical strains, 1149/2004, used as a 389 
recipient were highly promising regarding potential use indicating a decrease of over three 390 
orders of magnitude of the number of transconjugants upon pAZAKT mobilization. 391 
However, the number of pAZAKT transconjugants of another E. coli clinical strain tested, 392 
1355/2004, was reduced to a lesser extent (only by a factor of 40). The mobilization 393 
efficiency to the 1355/2004 recipient was ca. five orders of magnitude lower compared to 394 
the laboratory strain and that effect was not related to the presence of a conjugative IncP 395 
plasmid in the recipient. Another potential reason for the poor plasmid mobilization into the 396 
1355/2004 strain could stem from its mucoid phenotype. It has been suggested that the 397 
capsule constitutes a physical barrier for DNA (41), lowering the rate of horizontal gene 398 
transfer. However, recent findings (42) indicate that bacteria with capsule systems are more 399 
genetically diverse and have fast-evolving gene repertoires, suggesting intensive genetic 400 
exchange. At present, the reason for the lower population-reducing effect observed for the 401 
1355/2004 strain remains unknown.  402 
The analysis of the JE2571Rif
r
 transconjugants surviving pAZAKT transfer showed 403 
that it was not due to the development of Zeta-resistance. The survivors contained either an 404 
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inactivated zeta gene or a recombinant of pAZAKT and the epsilon-encoding plasmid from 405 
the donor, most probably due to the activity of chromosomally encoded IS1 (43).  406 
In summary, we have constructed a novel tool for plasmid mobilization based on the 407 
pCTX-M3 conjugation system: the pMOBS helper plasmid; the E. coli helper strains S14, 408 
S15, S25, and S26; and mobilizing vectors that can easily be modified to fit specific 409 
requirements. The system can mobilize oriTpCTX-M3-containing plasmids into a broad range 410 
of hosts, including not only Alpha-, Beta-, and Gammaproteobacteria, but also the Gram-411 
positive bacteria B. subtilis and L. lactis, and thus can be used in a variety of 412 
biotechnological applications.  413 
 414 
MATERIALS AND METHODS 415 
Bacterial strains and growth conditions. The strains used in this work are listed in 416 
Table 1. E. coli DH5α was used as the host strain for DNA cloning. In mating experiments, 417 
DH5α bearing pCTX-M3 or its derivatives (Table 2) was used as a donor. E. coli strain 418 
JE2571Rif
R
 or the clinical E. coli isolates 1355/04 and 1149/04 were used as recipients. In 419 
trans-species matings, Pseudomonas putida, Cupriavidus necator, Agrobacterium 420 
tumefaciens, Bacillus subtilis, and Lactococcus lactis were used as recipients. Bacteria were 421 
cultured with agitation in LB medium (Biocorp, Warsaw, Poland) or on agar-solidified LB 422 
plates (44) at either 37°C (E. coli, P. putida and B. subtilis) or 30°C (A. tumefaciens and C. 423 
necator). L. lactis was cultured without agitation in GM17 (M17 broth from Oxoid Ltd., 424 
Basingstoke, United Kingdom, with 0.5% glucose) or on agar-solidified GM17 plates. When 425 
required, antibiotics were added to the medium at the following final concentrations (µg/ml): 426 
ampicillin, 100; chloramphenicol, 20; kanamycin, 50; rifampicin, 100; spectinomycin, 100; 427 
tetracycline, 20. 428 
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DNA cloning and manipulation. Plasmid DNA was isolated by the alkaline lysis 429 
method using A&A Biotechnology Mini or Midi Plasmid kits (Gdańsk, Poland) according to 430 
the manufacturer’s instructions. For isolation of plasmid DNA from B. subtilis or L. lactis, 431 
20 µg/ml lysozyme (Serva, Heidelberg, Germany) was added to solution L1, followed by a 432 
30-min incubation at 37°C. Cloning procedures were performed according to standard 433 
protocols (44). All enzymes used for cloning were obtained from Thermo Fisher Scientific 434 
(Waltham, MA, USA). 435 
Plasmid construction. Plasmids used in this study are listed in Table 2. The pMOBS 436 
plasmid was constructed as follows. First, short sequences flanking the tra and trb regions 437 
(flanks) were PCR-amplified from the pCTX-M3 template except for the downstream flank 438 
of trb, which was amplified from pCTX-M3orf46::cat using primers listed in Table 3. 439 
Initially, the four amplified flanks were cloned independently into the pUC18 vector to give 440 
pUCA0118, pUCA0218, pUCA0318, pUCB0219 and pUCB0318 plasmids (Fig. S1A). 441 
Next, both flanks of tra were cloned together, the pUCA0218 KpnI-SalI fragment was 442 
transferred into KpnI-SalI digested pUCA0318 to give pUCA3218. Similarly, both trb 443 
flanks were cloned together, the SalI-KpnI fragment from pUCB0318 was introduced into 444 
the SalI-KpnI site of pUCB0219 to give pUCB3219. pUCB3219 was cut with Bsp1407I to 445 
give pUCB3219B for subsequent cloning. pUCA3218 and pUCB3219B contained terminal 446 
parts of the tra and trb regions, respectively. Further cloning was carried out in pLD1 (a 447 
derivative of pLDR10 devoid of the chloramphenicol resistance gene, carrying an attP 448 
sequence): the EcoRI-BamHI fragment from pUCB3219B was cloned into pLD1, resulting 449 
in pLDB, which then received the HindIII-BamHI fragment of pUCA3218 to generate 450 
pLDAB (Fig. S1A). The high copy-number replicon (oriVpMB1) from pLDAB was replaced 451 
by the PCR-amplified (primers FrepCNI and RrepANB2, pBS3-1 as a template) low copy-452 
number replicon of pCTX-M3 (oriVpCTX-M3) to obtain pLMAB2. Then, the central Bsp1407I-453 
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Bsp1407I fragment of the trb region from pSN17 was introduced into pLMAB2 to give 454 
pLMAB202, which next received the central AatII-NheI fragment of the tra region from 455 
pSS29 to give pLMAB212 (33614 bp), as presented in Fig. S1B.  456 
To make pLMAB212 unable to self-propagate, mutations in the nick region were 457 
introduced as follows. Regions surrounding the nick region were amplified from 458 
pLMAB212 (primer pairs FAatII-RnicSpe and FnicSpe-RPshAI) to introduce a site 459 
recognized by the SpeI restrictase in the nick region. These fragments were cloned 460 
individually in pAL3 (plasmids pAL-AS14 and pAL-SP3) and then combined to give 461 
pALAP. Next, the kanamycin resistance gene amplified from pET28a+ (primers FKanSpe2 462 
and RKanSpe) was cloned into the SpeI site introduced into the nick region of pALAP to 463 
produce pALAPK1. Then, the AatII-PshAI fragment from pALAPK1 replaced the 464 
appropriate fragment in pLMAB212 to create pMOBSK (transformants were selected on 465 
kanamycin-containing LB plates). Finally, the kanamycin resistance gene (the SpeI-SpeI 466 
fragment) was removed from pMOBSK to give pMOBS. The mutated oriTpCTX-M3 sequence 467 
in pMOBS  is shown in Fig. S1C. 468 
Construction of pAZAKT. The zeta gene was PCR-amplified from pBT233 469 
(primers EcoZetaFor and ZetaRevBam) and then the EcoRI (blunted)-BamHI fragment was 470 
cloned into pET28a+ digested with NdeI (blunted)-BamHI to give pET-zeta12. The BglII-471 
SalI fragment of pET-zeta12, comprising zeta, was cloned into BglII-SalI-digested 472 
pACYC184 to produce pACYC-zeta. Then, the 114-bp XbaI-NheI fragment containing 473 
PBAD, the arabinose operon promoter from pBAD24, amplified with upTEM and 474 
ARA1down (Table 3), was cloned into XbaI-digested pACYC-Zeta. The plasmid with 475 
proper orientation of PBAD was called pAZA. Next, the NaeI-BsiWI fragment comprising 476 
oriTpCTX-M3 and the kanamycin resistance gene from pABB20oriT was introduced in TatI-477 
PvuII-digested pAZA to give pAZAKT. All zeta bearing plasmids were constructed in 478 
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DH5α(pUC-epsi), an Epsilon producing strain. The activity of the zeta gene in each of the 479 
constructed plasmids was verified by a co-transformation assay with pUC-epsi (11). 480 
Construction of pAAKT. pAZAKT was digested with SpeI, blunted and re-ligated, 481 
resulting in pAAKT with a frame-shift in the 78
th
 codon of the zeta gene. The lack of 482 
activity of the zeta gene in pAAKT was verified by co-transformation with pUC-epsi (11). 483 
Strain construction. The S14 strain, with the tra and trb modules integrated into the 484 
chromosomal attB site, was constructed by transforming E. coli DH5α(pLDR8) (45), 485 
carrying the λ phage integrase gene, with the circularized DNA comprising the pMOBS 486 
plasmid devoid of the Eco31I-Eco31I fragment containing oriVpCTX-M3 and blaTEM-1 (Fig. 487 
S2A). A strain devoid of pLDR8 was selected by colony purification. The correct 488 
chromosomal integration of the tra and trb regions was verified by multiplex PCR (Fig. 489 
S2B) with primers specified in Table 3. 490 
Strain S15 was constructed by elimination of the cat gene from the chromosome of 491 
S14 with the use of the Flp recombinase encoded by pCP20 according to the method 492 
described by Datsenko and Wanner (23). Next, S15(pKD46) was transformed with DpnI-493 
treated PCR-amplified orf36::cat (generated using primers orf36uP1 and orf36dP2 on pKD3 494 
as a template, Table 3) to inactivate orf36 by replacement with the cat gene to give the S25 495 
strain. S26 is an S25 derivative with cat eliminated with the use of Flp recombinase encoded 496 
by pCP20. The correctness of the cat elimination or insertion was verified by PCR with 497 
primers pCTX96 and orf36sU (Table 3). 498 
PCR conditions. PCR was performed in a Veriti Thermal Cycler (Applied 499 
Biosystems, Foster City, CA, USA) using DreamTaq DNA polymerase with supplied 500 
buffers (Thermo Fisher Scientific), dNTP mixture and a template (purified DNA or bacterial 501 
cells), with appropriate primer pairs listed in Table 3, according to manufacturer’s 502 
recommendations. Pfu DNA polymerase was used for the generation of DNA fragments that 503 
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were used in the construction of pMOBS and strain S14 as well as for amplification of the 504 
PBAD promoter and of orf36::cat for construction of the S25 strain.  505 
Plasmid conjugative transfer. Generally, matings were performed as described 506 
previously (21). B. subtilis was grown in LB to stationary phase (approximately 10
8 
CFU 507 
ml
-1
), washed twice with LB medium and resuspended in one-fourth of the initial culture 508 
volume. The mixture of the donor and recipient was filtered through a sterile Millipore HA 509 
0.45 µm filter (Millipore, Billerica, MA, USA). The filter was then incubated on an LB plate 510 
at 30°C for 24 h (B. subtilis) or 2 h (Gram-negative bacteria). When B. subtilis was the 511 
recipient, LB plates containing DNase I (100 U/ml) were used. The E. coli – L. lactis 512 
matings were performed similarly, except that the L. lactis recipient was prepared as 513 
described by Bogusławska et al. (46) from exponentially grown culture, and after the donor 514 
and recipient were filtered, the filter was incubated on a BHI (Oxoid Ltd) plate with DNase I 515 
(100 U/ml) at 30°C for 24 h. The conjugation was stopped by vigorous vortexing of the 516 
mating mixture for 30 s and then placing it on ice. Serial dilutions of the donor, recipient, 517 
and mating mixture were plated on selective LB agar (or GM17 for L. lactis) supplemented 518 
with appropriate antibiotics. The efficiency of conjugative transfer is expressed as the 519 
number of transconjugants per donor cell. As a control, dilutions of the donor and recipient 520 
cells were plated on LB (or GM17 for L. lactis) supplemented with the antibiotics 521 
appropriate for transconjugant selection.  522 
Mobilization-mediated Zeta killing assays. The mobilization-mediated Zeta killing assay 523 
was performed following mating as described previously (21) with modifications involving 524 
the use of an excess of donors. The recipients were in either the stationary or the exponential 525 
phase of growth. In experiments with recipient cells in the stationary phase, 50 µl of a 526 
recipient suspension (4.6×10
5
 per
 
ml) was mixed with 950 µl of a donor suspension (initial 527 
concentration 7.0×10
9 
per
 
ml) diluted 1-, 10- or 100-fold. For recipients in the exponential 528 
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phase of growth (OD600=0.4) the conjugation mixture was composed of 500 µl of the donor 529 
suspension (1.2×10
9
 per
 
ml) and 500 µl of 1-, 10-, 100- or 1000-fold diluted recipient 530 
suspension (initial concentration 4.0×10
8
 per
 
ml). Following conjugation the number of Rif
r
 531 
cells was compared with the initial number of recipients to establish the recipient survival 532 
rate. 533 
534 
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TABLES 725 
Table 1. Bacterial strains used in this study. 726 
Species                    Strain Genotype or relevant feature Source 
Escherichia coli 
DH5α 
ϕ80 lacZΔM15 deoR endA1 gyrA96 hsdR17 recA1 relA1 
supE44 thi-1 Δ(lacZYAargF)U169 
(47) 
DH5αRifr DH5α selected on LB with rifampicin This work 
JE2571Rifr JE2571 selected on LB with rifampicin (21) 
S14 
DH5α with the pCTX-M3 tra-trb genes integrated, Δorf35, 
orf46::cat; Cmr 
This work 
S15 S14 with Δorf46, Cms This work 
S25 S15 with orf36::cat; Cmr This work 
S26 S25 with Δorf36; Cms This work 
1149/2004 Clinical isolate; Apr, Tcr, Str r; replicons: IncFIB, IncI1, IncP  
Collection of National 
Institute of Medicines (48) 
1355/2004   Clinical isolate; Apr, Tcr, Strr; replicon: IncP Collection of National 
Institute of Medicines (48) 
Bacillus subtilis 
YB1015 amyE metB trpC xin-1 attSPβ recA (49) 
YB1015Rifr YB1015 selected on LB with rifampicin This work 
PCM 2021 Biofilm forming strain 
Polish Collection of 
Microorganisms 
PCM 2021Rifr PCM 2021 selected on LB with rifampicin This work 
Lactococcus lactis 
IL1403  (50) 
IL1403Rifr IL1403 selected on GM17 with rifampicin This work 
Agrobacterium 
tumefaciens 
LBA1010  Rifr (51) 
Pseudomonas putida KT2442  Rifr (52) 
Cupriavidus necator 
(previously Ralstonia 
eutropha) 
JMP228 Rifr, gfp, Kmr (53) 
 727 
728 
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Table 2. Plasmids used in this work. 729 
Name Relevant feature or construction description Source 
pCTX-M3 and its derivative 
pCTX-M3 IncM plasmid, 89468 bp; Apr, Pir, Azt r, Caz r, Cftr, Kmr, Genr, Tor (15, 54) 
pCTX-M3orf46::cat 
pCTX-M3 with orf46 replaced with the cat gene; Apr, Pir, Azt r, Caz r, Cftr, Kmr, Genr, Tor, 
Cmr 
(21) 
Cloning vectors 
pABB19 cloning vector; oriVpMB1, Ap
r   (55) 
pACYC184 cloning vector; oriVP15A, Tc
r, Cmr (56) 
pAL3 cloning vector oriVP15A, Tc
r (21) 
pBAD24 vector, PBAD promoter of araBAD (arabinose) operon, oriVpMB1, Ap
r (57) 
pBBR1 MCS-2 vector; oriVpBBR1, oriTRK2, Km
r   (24) 
pBSU100 E. coli – Firmicutes shuttle vector; oriVpMB1, oriVpAMβ1, egfp, Sp
r, Apr    (58) 
pBSU1 pBSU100 with deleted egfp containing fragment SacI-SphI (oriVpMB1, oriVpAMβ1, Sp
r) This work 
pCP20 Flp recombinase expression plasmid; repA101(ts), oriVR101, Ap
r, Cmr (39) 
pET28a+ vector, oriVpMB1, Km
r  Novagen 
pKD3 
template for generation of the cat gene containing flanks for gene disruption, pir-dependent 
replicon; oriVR6Kγ, Ap
r, Cmr 
(23) 
pKD46 λRed recombinase expression plasmid; repA101(ts), oriVR101, Ap
r (23) 
pLDR8 helper plasmid for integration; int(λ) gene, oriVpSC101, Km
r (45) 
pLDR10 vector for integration into attB; attP, oriVP15A, Ap
r, Cmr (45) 
pUC18 cloning vector; oriVpMB1, Ap
r   (59) 
pUC19 cloning vector; oriVpMB1, Ap
r (59) 
Plasmids carrying oriTpCTX-M3 
pALoriT 
pOriT EcoRI-PstI fragment containing oriTpCTX-M3 cloned into EcoRI-PstI pAL3 (oriVp15A, 
TcR) 
This work 
pABB19oriT 
pOriT BamHI-PstI fragment containing oriTpCTX-M3 (31616-31721)* cloned into BamHI-
PstI of pABB19 (oriVpMB1, Ap
r) 
This work 
pBBToriT 
pALoriT XbaI-PvuI fragment containing tetracycline resistance gene and oriTpCTX-M3 cloned 
into PvuI-XbaI pBBR1MCS-2 (oriVpBBR1, Tet
R) 
This work 
pBSUoriT 
pOriT PaeI-SacI fragment containing oriTpCTX-M3 cloned into PaeI-SacI of pBSU1 
(oriVpMB1, oriVpAMβ1, Sp
r) 
This work 
pOriT oriTpCTX-M3 (31616-31721)* in pMI3 vector (oriVpMB1, Cm
r)  (15) 
pToriT pBBToriT derivative, fragment BsaI-Bst1107I with MOBRK2 removed (oriVpBBR1, Km
r, Tcr)  
This work 
 
 Plasmids used for tra and trb assembly and pMOBS construction   
pALAP pAL-SP3 SpeI-PstI fragment cloned into SpeI-PstI of pAL-AS14  This work 
pALAPK1 pET28a+ fragment (3943-4832), contains kanamycin resistance gene amplified with primers 
FKanSpe2# and RKanSpe# (SpeI) cloned into SpeI of pALAP 
This work 
pAL-AS14 pLMAB212 fragment (92-359) amplified with primers FAatII# and RnicSpe#, cloned into 
SmaI of pAL3 
This work 
pAL-SP3 pLMAB212 fragment (356-1622) amplified with primers FnicSpe# and RPshAI#, cloned into 
SmaI of pAL3 
This work 
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pBS3-1 pCTX-M3 minireplicon; fragment Bst1107I-StuI (54309-57986)*, Apr  This work 
pHS11 pCTX-M3 derivative SexAI-SnaBI (36645-40568)* and NruI-SalI (51663-58653)* fragments This work 
pLD1 pLDR10 derivative, removed fragment BsmI (1713-2120)  This work 
pLDAB pUCA3218 HindIII-BamHI fragment cloned into HindIII-BamHI of pLDB This work 
pLDB pUCB3219B EcoRI-BamHI fragment cloned into EcoRI-BamHI of pLD1 This work 
pLMAB2 pBS3-1 (3624-2152) fragment containing pCTX-M3 replicon, amplified with primers 
FRepCNI# and RepANB2# (NotI), cloned into NotI of pLDAB 
This work 
pLMAB202 pSN17 Bsp1407I (11410-14854; 84420-87864)* fragment cloned into Bsp1407I of 
pLMAB2 
This work 
pLMAB212 AatII-NheI pSS29 fragment cloned into AatII-NheI of pLMAB202;  tra (30634-59557)* 
and trb (84101-89015)* of pCTX-M3,oriTpCTX-M, oriVpCTX-M3, Ap
r 
This work 
pMOBS pMOBSK derivative, removed the SpeI-SpeI fragment with the kanamycin resistance gene; 
tra (30634-59557)* and trb (84101-89015)* of pCTX-M3, oriVpCTX-M3, Cm
r, Apr  
This work 
pMOBSK pALAPK1 AatII-PshAI fragment cloned into AatII-PshAI of pLMAB212 This work 
pSN17 pCTX-M3 orf46::cat derivative, NdeI-SphI (53187-59797)* and SphI –NdeI(80753–626)* 
fragments 
This work 
pSS29 pCTX-M3 derivative, SwaI-SalI (30630–59552)* and SalI-SwaI (64145–64426)* fragments This work 
pUCA0118 pCTX-M3 (31285-32022)* fragment amplified with primers FtraHind# and RtraPst # 
(HindIII, PstI), cloned into HindIII-PstI of pUC18 
This work 
pUCA0218 pCTX-M3 (52154-54408)* fragment amplified with primers FtraSa#l and RtraXba# (SalI, 
XbaI), cloned into SalI-XbaI of pUC18 
This work 
pUCA0318 pUCA0118 derivative with substitutions in the nic sequence introduced with primers 
FnicM# and RnicM# 
This work 
pUCA3218 KpnI-SalI pUCA0218 fragment cloned into KpnI-SalI of pUCA0318 This work 
pUCB0219 pCTX-M3 (87807-89020)* fragment amplified with primers FtrbNco-Sac#-RtrbEco# (SacI, 
EcoRI), cloned into SacI-EcoRI of pUC19 
This work 
pUCB0318 pCTX-M3 orf46::cat fragment (83021-85053)* amplified with primers FtrbXba# and 
RtrbBam#, cloned into SmaI of pUC18  
This work 
pUCB3219 SalI-KpnI pUCB0318 fragment cloned into SalI-KpnI of pUCB0219 This work 
pUCB3219B pUCB3219 derivative, fragment Bsp1407I (1543-1729) removed This work 
 Plasmids coding for zeta or epsilon  
pUC-epsi 
pACE1 EcoRI-HincII fragment containing epsilon gene cloned into EcoRI-HincII digested 
pUC18; oriVpMB1, Ap
r   
This work 
pUC-epsiSH 
shortened pUCepsi after Bsp119I and EheI digestion, the sticky ends were blunted and re-
ligated ; oriVpMB1, Ap
r   
This work 
pBT233 pSM19035 derivative, Acc. No. X64695 (60) 
pET-zeta12 pET28a+ with zeta cloned in NdeI (blunted)-BamHI This work 
pACYC-zeta pACYC184 with zeta gene, oriVP15A, Cm
r This work 
pACE1 pACYC184 with epsilon gene of pSM19035, oriVP15A, Tc
r (11) 
pAZA pACYC-Zeta with PBAD, oriVP15A, Cm
r This work 
pAZAKT pAZA with oriTpCTX-M3, the zeta gene under control of PBAD , oriVP15A, Km
r, oriTpCTX-M3 This work 
pAAKT 
pAZAKT SpeI-digested, filled-in, re-circularized, inactive zeta gene under control of PBAD, 
oriVP15A, Km
r, oriTpCTX-M3 
This work 
Ap – ampicillin, Azt - aztreonam, Cft - cefotaxim, Caz - ceftazidime, Cm – chloramphenicol, Gen - gentamicin, Pi - piperacillin, Sp - 730 
spectinomycin, Tc –tetracyclin, To - tobramycin; (ts) - thermosensitive 731 
*pCTX-M3 coordinates (Acc. No. AF550415); 732 
# primers listed in Table 3 733 
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Table 3. Primers used in this work. 734 
Primer Sequence 5’-3’  PCR template 
 Primers for tra trb assembly  
FtraHind CATACCCTTTCGAAGCTTTCAGC pCTX-M3 
RtraPst CTCCTGCTGCAGTTTCTGTGC pCTX-M3 
FnicM GTACGGGACAATATTGGTTTTTGGAGTACCGC pCTX-M3 
RnicM CTCCAAAAACCAATATTGTCCCGTACTTAAATACC pCTX-M3 
FtraSal GCAGGGTCGACTTCTATCTTCGCTAGCGG pCTX-M3 
RtraXba ACTCTCTCTAGAACTCCGGGTTAC pCTX-M3 
FtrbXba AGATCTAGAAAACGTTGCTTAACGTGAG pCTX-M3 
orf46::cat 
RtrbBam TTCCAGGATCCCCTGGTACGCAGCGCAG pCTX-M3 
orf46::cat 
FtrbNco-Sac CGGTTGAGCTCGTCGAGAATGGATTTAGC pCTX-M3 
RtrbEco AATAGAATTCCTCTGACACCCTCTC pCTX-M3 
FrepCNI GTGGCGGCCGCGTAAGAAACCATTATTATC pBS3-1 
RrepANB2 TAGGCGGCCGCGGTCTCGCACCCCTGCCGTCTTACG pBS3-1 
 Primers for nick region mutagenesis  
FAatII TTCTGACGTCACATCAGGCAAGTCG pLMAB212 
RnicSpe AACCGAACTAGTCCCGTACTTAAATACCTC pLMAB212 
FKanSpe2 GAACTAGTCATGAACAATAAAACTGTCTGC pET28a+ 
RKanSpe AGACTAGTATCCGCTCATGAATTAATTC pET28a+ 
FnicSpe GGACTAGTTCGGTTTTTGGAGTACCGCCGACAC pLMAB212 
RPshAI GAAGACCGATGTCTGCAAATGTCTTATGC pLMAB212 
 Primers for Kan-oriT cloning  
FKanAatII ATGGACGTCAGCTACTGGGCTATCTGG pToriTB 
oriTminDAatII TTGGACGTCTGCAGAGATAGCTAACCTCGTTAGG pToriTB 
 Primers for orf36 replacement with cat  
orf36uP1 ATGCAAACAGTGATGCATTCCCGTTCCATTTGTAACGTGTAGGCTG
GAGCTGCTTCG 
pKD3 
orf36dP2 GAACAATGAGGTATACATGAGCGAACATAATGATTATATATGAAT
ATCCTCCTTA 
pKD3 
 Primers for integration verification  
ybhB122 CTGGCAAGCGCCTCGATTAC  
ybhC159 ACCAGGCGCGGTTTGATCAG  
orf35UEc TCGAATTCGACATTATTGGGAGGGC  
FtrbNco-Sac CGGTTGAGCTCGTCGAGAATGGATTTAGC  
pCTX96 CCGAGTCAGTTTGATCCATA  
orf36sU GGATGAGGTATGCAATACGG  
 Primers for cloning of zeta gene  
EcoZetaFor GCC GAA TTC ATG GCA AAT ATA GTC AAT TTT ACT pBT233 
ZetaRevBam GCC GGA TCC TTA AAT ACC TGG AAG TTT AGG TGT  
 Primers for cloning of PBAD promoter  
upTEM CACCAGCGTTTCTGGGTGAG pBAD24 
ARA1down GCTCTAGAGGCGTCACACTTTGCTATGC  
 Primers for epsilon detection  
EpsiS* TGAAATGGCAGTTACGTATG  
EpsiE* TGCCATATTAAGCCACTTTC  
    relevant restriction sites are underlined 735 
* epsilon start and stop codons are bolded 736 
 737 
738 
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FIGURES 739 
 740 
Figure 1. Conjugation and pALoriT (oriTpCTX-M3, oriVp15A, Tc
R
) mobilization efficiencies 741 
from E. coli donors with pLMAB212 or pMOBS into the JE2571Rif
r 
recipient. Each result is 742 
the mean of four experiments. # undetectable transfer. Error bars indicate SD.  743 
 744 
 745 
Figure 2. Mobilization efficiency of pToriT from strains: DH5α(pCTX-M3), 746 
DH5α(pMOBS), and S14 into E. coli JE2571Rifr. Each result is the mean of four 747 
experiments. Error bars indicate SD.  748 
 749 
 750 
 751 
Figure 3. Mobilization efficiency of pToriT by strains S14, S15, S25, and S26 into E. coli 752 
JE2571Rif
r
 and by S15 and S26 into different Proteobacteria recipients. Each result is the 753 
mean of four experiments. Error bars indicate SD. 754 
 755 
 756 
Figure 4. Mobilization efficiency of pBSUoriT from strain S25 into the Gram-positive 757 
recipients B. subtilis (A) and L. lactis (B). For comparison, efficiency of plasmid 758 
mobilization into E. coli JE2571Rif
r
 is shown. Each result is the mean of four experiments. 759 
Error bars indicate SD. 760 
 761 
 762 
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Figure 5. Mobilization efficiencies of pAZAKT and pAAKT by strain S26(pUC-epsi) into 763 
E. coli recipients JE2571Rif
r 
and DH5Rifr. Each result is the mean of four experiments. 764 
Error bars indicate SD. 765 
 766 
 767 
Figure 6. Mobilization-mediated Zeta killing. Mobilization of pAZAKT or pAAKT from 768 
the S26(pUC-epsi) donor into E. coli JE2571Rif
r
 as a recipient in stationary growth phase 769 
(A) and exponential growth phase (B) with various donor-to-recipient ratios. Each result is 770 
the mean of three experiments. Error bars indicate SD. 771 
 772 
 773 
Figure 7. Mobilization efficiency of pToriT from strain S26 into clinical E. coli strains 774 
1355/2004 and 1149/2004. For comparison, efficiency of plasmid mobilization into E. coli 775 
JE2571Rif
r
 is shown. Each result is the mean of four experiments. Error bars indicate SD. 776 
 777 
 778 
Figure 8. Effect of mobilization of pAZAKT and pAAKT from the S26(pUC-epsi) donor 779 
into clinical strains 1149/2004 and 1355/2004 (A) and JE2571Rif
r
 carrying IncP plasmid 780 
from strain 1355/2004 - R
+
[E. coli 1355/2004] (B). For comparison, efficiency of plasmid 781 
mobilization into E. coli JE2571Rif
r
 is shown. Each result is the mean of at least three 782 
experiments. Error bars indicate SD.  783 
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